Anthropic is creating its own medicines not just to enter pharma, but to gain hands-on experience using its AI products to solve real scientific problems. This internal R&D effort is a strategy to improve their core large language model for scientific use, potentially giving them a competitive edge.
The affordability crisis has pushed small businesses past trimming benefits to completely giving up on offering health insurance. Many conclude it's too expensive and complicated, marking a significant breakdown of the long-standing employer-based coverage model that began after World War II.
The core driver of high insurance costs is the unregulated and widely variable prices charged for identical products and services. Different insurers pay vastly different amounts for the same thing, a market failure hidden from consumers by fixed co-pays, which ultimately leads to ever-increasing premiums for employers.
New Jersey's $100 million settlement with Horizon Blue Cross was contingent on whistleblower Chris Deacon being stripped of her official status. She had to sign the deal, effectively silencing her role, or the state would lose the money and she would face potential litigation, revealing a powerful tactic used against whistleblowers.
Employers contribute to soaring health costs not through ill will, but by an unwillingness to challenge the status quo. It is easier to accept industry-wide rate hikes than to ask uncomfortable questions, scrutinize data, or sever long-term relationships with brokers and insurers, thus perpetuating the high-cost cycle.
The convoluted nature of the health insurance system is not an accident; it is a strategic asset for incumbents. The resulting confusion causes exasperation among employers and consumers, preventing them from effectively questioning costs or believing they can enact change, thereby protecting the industry's profitable, high-cost model.
By waiting until Q3 to shop for the next year's health plan, employers inadvertently box themselves in. This compressed timeline leaves no room to explore and implement fundamentally different, cost-saving models. Breaking the cycle requires starting the procurement process months earlier than is conventional.
Vertex demonstrates a methodical approach to building its post-cystic fibrosis pipeline. Under its current CEO, the company started with sub-$1 billion deals to "get their feet wet" before escalating to larger acquisitions like the $4.9B Alpine deal and now the $10B Crenetics deal, indicating a carefully managed increase in scale and risk.